BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F. Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure. Gut 2015;64:1314-26. [PMID: 25670809 DOI: 10.1136/gutjnl-2014-308943] [Cited by in Crossref: 196] [Cited by in F6Publishing: 185] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Ye L, Kan F, Yan T, Cao J, Zhang L, Wu Z, Li W. Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice. Sci Rep 2017;7:3860. [PMID: 28634402 DOI: 10.1038/s41598-017-04170-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Loureiro A, da Silva GJ. CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool. Antibiotics (Basel) 2019;8:E18. [PMID: 30823430 DOI: 10.3390/antibiotics8010018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
3 Jacobi FJ, Wild K, Smits M, Zoldan K, Csernalabics B, Flecken T, Lang J, Ehrenmann P, Emmerich F, Hofmann M, Thimme R, Neumann-haefelin C, Boettler T. OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection. Journal of Hepatology 2019;70:1103-13. [DOI: 10.1016/j.jhep.2019.02.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
4 Gill US, Kennedy PTF. The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. J Viral Hepat 2018. [DOI: 10.1111/jvh.13040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zoulim F. Inhibition of hepatitis B virus gene expression: A step towards functional cure. J Hepatol 2018;68:386-8. [PMID: 29217272 DOI: 10.1016/j.jhep.2017.11.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
6 Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol 2016;64:S4-S16. [PMID: 27084035 DOI: 10.1016/j.jhep.2016.01.027] [Cited by in Crossref: 186] [Cited by in F6Publishing: 184] [Article Influence: 37.2] [Reference Citation Analysis]
7 Świderska M, Jaroszewicz J, Parfieniuk-Kowerda A, Rogalska-Płońska M, Stawicka A, Panasiuk A, Flisiak R. Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. Mediators Inflamm 2017;2017:3480234. [PMID: 28827897 DOI: 10.1155/2017/3480234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
8 Akbar SM, Al-Mahtab M, Khan MS, Raihan R, Shrestha A. Immune therapy for hepatitis B. Ann Transl Med 2016;4:335. [PMID: 27761439 DOI: 10.21037/atm.2016.08.48] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Podlaha O, Gane E, Brunetto M, Fung S, Chuang WL, Pan CQ, Jiang Z, Liu Y, Bhardwaj N, Mukherjee P, Flaherty J, Gaggar A, Subramanian M, Izumi N, Shalimar, Lim YS, Marcellin P, Buti M, Chan HLY, Agarwal K. Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. Sci Rep 2019;9:10529. [PMID: 31324819 DOI: 10.1038/s41598-019-46609-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
10 Li D, He W, Liu X, Zheng S, Qi Y, Li H, Mao F, Liu J, Sun Y, Pan L, Du K, Ye K, Li W, Sui J. A potent human neutralizing antibody Fc-dependently reduces established HBV infections. Elife 2017;6:e26738. [PMID: 28949917 DOI: 10.7554/eLife.26738] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
11 Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS 2017;31:2035-52. [PMID: 28692539 DOI: 10.1097/QAD.0000000000001574] [Cited by in Crossref: 120] [Cited by in F6Publishing: 71] [Article Influence: 24.0] [Reference Citation Analysis]
12 Wang YX, Niklasch M, Liu T, Wang Y, Shi B, Yuan W, Baumert TF, Yuan Z, Tong S, Nassal M, Wen YM. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication. J Hepatol. 2020;72:865-876. [PMID: 31863794 DOI: 10.1016/j.jhep.2019.12.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
13 Noverati N, Bashir-Hamidu R, Halegoua-DeMarzio D, Hann HW. Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress. Int J Mol Sci 2022;23:3917. [PMID: 35409275 DOI: 10.3390/ijms23073917] [Reference Citation Analysis]
14 Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392:2313-2324. [PMID: 30496122 DOI: 10.1016/s0140-6736(18)31865-8] [Cited by in Crossref: 139] [Cited by in F6Publishing: 62] [Article Influence: 46.3] [Reference Citation Analysis]
15 Durantel D. New treatments to reach functional cure: Virological approaches. Best Pract Res Clin Gastroenterol. 2017;31:329-336. [PMID: 28774415 DOI: 10.1016/j.bpg.2017.05.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
16 Dandri M. Epigenetic modulation in chronic hepatitis B virus infection. Semin Immunopathol 2020;42:173-85. [PMID: 32185454 DOI: 10.1007/s00281-020-00780-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
17 Yang L, Liu F, Tong X, Hoffmann D, Zuo J, Lu M. Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. ACS Infect Dis 2019;5:713-24. [PMID: 30896149 DOI: 10.1021/acsinfecdis.8b00337] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
18 Ezzikouri S, Kayesh MEH, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines (Basel) 2020;8:E216. [PMID: 32403281 DOI: 10.3390/vaccines8020216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Verrier ER, Schuster C, Baumert TF. Advancing hepatitis B virus entry inhibitors. J Hepatol 2017;66:677-9. [PMID: 27965159 DOI: 10.1016/j.jhep.2016.11.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
20 Soriano V, Aguilera A. Hepatitis Delta Enters a New Therapeutic Era. The Journal of Infectious Diseases 2018;217:1173-6. [DOI: 10.1093/infdis/jix658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
21 Zheng J, Ou Z, Xu Y, Xia Z, Lin X, Jin S, Liu Y, Wu J. Hepatitis B virus-specific effector CD8+ T cells are an important determinant of disease prognosis: A meta-analysis. Vaccine 2019;37:2439-46. [PMID: 30935741 DOI: 10.1016/j.vaccine.2019.03.058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Long KR, Lomonosova E, Li Q, Ponzar NL, Villa JA, Touchette E, Rapp S, Liley RM, Murelli RP, Grigoryan A, Buller RM, Wilson L, Bial J, Sagartz JE, Tavis JE. Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice. Antiviral Res 2018;149:41-7. [PMID: 29129708 DOI: 10.1016/j.antiviral.2017.11.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
23 Dai X, Zhang X, Ostrikov K, Abrahamyan L. Host receptors: the key to establishing cells with broad viral tropism for vaccine production. Crit Rev Microbiol 2020;46:147-68. [PMID: 32202955 DOI: 10.1080/1040841X.2020.1735992] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
24 van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X, Tabak F, Streinu-Cercel A, Wang JY, Zhang NP, Idilman R, Reesink HW, Diculescu M, Simon K, Akdogan M, Mazur W, de Knegt RJ, Verhey E, Hansen BE, Janssen HLA; ARES Study Group. Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. J Viral Hepat 2019;26:109-17. [PMID: 30187612 DOI: 10.1111/jvh.12997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
25 Revill PA, Penicaud C, Brechot C, Zoulim F. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes (Basel) 2019;10:E260. [PMID: 30939846 DOI: 10.3390/genes10040260] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
26 Toka B, Eminler AT, Gönüllü E, Tozlu M, Uslan MI, Parlak E, Karabay O, Koksal AS. Rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive therapy. Rheumatol Int 2019;39:2077-85. [DOI: 10.1007/s00296-019-04437-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Isorce N, Testoni B, Locatelli M, Fresquet J, Rivoire M, Luangsay S, Zoulim F, Durantel D. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral Res. 2016;130:36-45. [PMID: 26971407 DOI: 10.1016/j.antiviral.2016.03.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
28 Zoulim F, Lebossé F, Levrero M. Current treatments for chronic hepatitis B virus infections. Curr Opin Virol 2016;18:109-16. [PMID: 27318098 DOI: 10.1016/j.coviro.2016.06.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
29 Yang S, Ma X, Cai C, Wang H, Xiao F, Yu C. Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study. Front Med (Lausanne) 2021;8:637126. [PMID: 33791326 DOI: 10.3389/fmed.2021.637126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Fan H, Lin L, Jia S, Xie M, Luo C, Tan X, Ying R, Guan Y, Li F. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B. J Viral Hepat 2019;26:77-84. [DOI: 10.1111/jvh.13165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
31 Zeisel MB, Baumert TF. Hepatitis B virus: is a cure possible? Expert Rev Clin Pharmacol 2016;9:1129-30. [PMID: 27347775 DOI: 10.1080/17512433.2016.1206466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Sugarman J, Revill P, Zoulim F, Yazdanpanah Y, Janssen HL, Lim SG, Lewin SR. Ethics and hepatitis B cure research. Gut 2017;66:389-92. [PMID: 27849559 DOI: 10.1136/gutjnl-2016-313009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
33 Minosse C, Coen S, Visco Comandini U, Lionetti R, Montalbano M, Cerilli S, Vincenti D, Baiocchini A, Capobianchi MR, Menzo S. Simple and Reliable Method to Quantify the Hepatitis B Viral Load and Replicative Capacity in Liver Tissue and Blood Leukocytes. Hepat Mon 2016;16:e28751. [PMID: 27882060 DOI: 10.5812/hepatmon.28751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Gill US, Kennedy PT. Current therapeutic approaches for HBV infected patients. Journal of Hepatology 2017;67:412-4. [DOI: 10.1016/j.jhep.2017.04.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
35 Lin G, Zhang K, Li J. Application of CRISPR/Cas9 Technology to HBV. Int J Mol Sci. 2015;16:26077-26086. [PMID: 26540039 DOI: 10.3390/ijms161125950] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
36 Su TH, Kao JH. Unmet Needs in Clinical and Basic Hepatitis B Virus Research. J Infect Dis 2017;216:S750-6. [PMID: 29156048 DOI: 10.1093/infdis/jix382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
37 Colson P, Raoult D. Fighting viruses with antibiotics: an overlooked path. Int J Antimicrob Agents 2016;48:349-52. [PMID: 27546219 DOI: 10.1016/j.ijantimicag.2016.07.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
38 Ito K, Okumura A, Takeuchi JS, Watashi K, Inoue R, Yamauchi T, Sakamoto K, Yamashita Y, Iguchi Y, Une M, Wakita T, Umezawa K, Yoneda M. Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo. Hepatology 2021;74:83-98. [PMID: 33434356 DOI: 10.1002/hep.31712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
39 Yoo J, Hann HW, Coben R, Conn M, DiMarino AJ. Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure. Diseases. 2018;6:E27. [PMID: 29677098 DOI: 10.3390/diseases6020027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
40 Chu Q, Li J, Chen J, Yuan Z. HBV induced the discharge of intrinsic antiviral miRNAs in HBV-replicating hepatocytes via extracellular vesicles to facilitate its replication. J Gen Virol 2022;103. [PMID: 35604380 DOI: 10.1099/jgv.0.001744] [Reference Citation Analysis]
41 Khalfaoui S, Eichhorn V, Karagiannidis C, Bayh I, Brockmann M, Pieper M, Windisch W, Schildgen O, Schildgen V. Lung Infection by Human Bocavirus Induces the Release of Profibrotic Mediator Cytokines In Vivo and In Vitro. PLoS One 2016;11:e0147010. [PMID: 26807786 DOI: 10.1371/journal.pone.0147010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
42 Malagnino V, Fofana DB, Lacombe K, Gozlan J. Occult Hepatitis B Virus Infection: An Old Entity With Novel Clinical Involvements. Open Forum Infect Dis 2018;5:ofy227. [PMID: 30324127 DOI: 10.1093/ofid/ofy227] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
43 Qi Y, Gao Z, Xu G, Peng B, Liu C, Yan H, Yao Q, Sun G, Liu Y, Tang D, Song Z, He W, Sun Y, Guo JT, Li W. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. PLoS Pathog 2016;12:e1005893. [PMID: 27783675 DOI: 10.1371/journal.ppat.1005893] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 14.7] [Reference Citation Analysis]
44 Wei J, Shi Y, Zou C, Zhang H, Peng H, Wang S, Xia L, Yang Y, Zhang X, Liu J, Zhou H, Luo M, Huang A, Wang D. Cellular Id1 inhibits hepatitis B virus transcription by interacting with the novel covalently closed circular DNA-binding protein E2F4. Int J Biol Sci 2022;18:65-81. [PMID: 34975318 DOI: 10.7150/ijbs.62106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
45 Fukano K, Tsukuda S, Oshima M, Suzuki R, Aizaki H, Ohki M, Park SY, Muramatsu M, Wakita T, Sureau C, Ogasawara Y, Watashi K. Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes. Front Microbiol 2018;9:3257. [PMID: 30671048 DOI: 10.3389/fmicb.2018.03257] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
46 O'Brien TR, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 2019;156:400-17. [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
47 Pan J, Tong S, Tang J. Alteration of microRNA profiles by a novel inhibitor of human La protein in HBV-transformed human hepatoma cells. J Med Virol 2018;90:255-62. [PMID: 28885699 DOI: 10.1002/jmv.24941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
48 Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol. 2017;66:685-692. [PMID: 27890789 DOI: 10.1016/j.jhep.2016.11.009] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 10.2] [Reference Citation Analysis]
49 Revill P, Testoni B, Locarnini S, Zoulim F. Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol. 2016;13:239-248. [PMID: 26907881 DOI: 10.1038/nrgastro.2016.7] [Cited by in Crossref: 107] [Cited by in F6Publishing: 99] [Article Influence: 17.8] [Reference Citation Analysis]
50 Akbar SM, Al-mahtab M, Khan SI, Shrestha A, Tabassum S, Hiasa Y. Current trends in hepatitis B vaccination. Future Virology 2016;11:369-78. [DOI: 10.2217/fvl-2016-0025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Hadziyannis SJ. Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen. Clin Gastroenterol Hepatol 2016;14:1499-501. [PMID: 27339695 DOI: 10.1016/j.cgh.2016.06.015] [Reference Citation Analysis]
52 Lomonosova E, Zlotnick A, Tavis JE. Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors. Antimicrob Agents Chemother 2017;61:e02441-16. [PMID: 27956427 DOI: 10.1128/AAC.02441-16] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
53 De Clercq E. Current treatment of hepatitis B virus infections: Current treatment of HBV Infections. Rev Med Virol 2015;25:354-65. [DOI: 10.1002/rmv.1849] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
54 Kinoshita W, Ogura N, Watashi K, Wakita T. Host factor PRPF31 is involved in cccDNA production in HBV-replicating cells. Biochem Biophys Res Commun 2017;482:638-44. [PMID: 27864147 DOI: 10.1016/j.bbrc.2016.11.085] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
55 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
56 Liu WL, Yang HC, Hsu CS, Wang CC, Wang TS, Kao JH, Chen DS. Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway. Proc Natl Acad Sci U S A 2016;113:14799-804. [PMID: 27930338 DOI: 10.1073/pnas.1618517114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
57 Hamada-Tsutsumi S, Naito Y, Sato S, Takaoka A, Kawashima K, Isogawa M, Ochiya T, Tanaka Y. The antiviral effects of human microRNA miR-302c-3p against hepatitis B virus infection. Aliment Pharmacol Ther 2019;49:1060-70. [PMID: 30828831 DOI: 10.1111/apt.15197] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
58 Li W, Urban S. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J Hepatol 2016;64:S32-40. [PMID: 27084034 DOI: 10.1016/j.jhep.2016.02.011] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 12.8] [Reference Citation Analysis]
59 Kayesh MEH, Kohara M, Tsukiyama-Kohara K. Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview. Int J Mol Sci 2021;22:10462. [PMID: 34638802 DOI: 10.3390/ijms221910462] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Höpken M, Förster I, Maune S, Brockmann M, Schildgen O, Schildgen V. Association of the Human Bocavirus With Tonsil Squamous Cell Carcinomas. Front Microbiol 2018;9:2450. [PMID: 30459721 DOI: 10.3389/fmicb.2018.02450] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
61 Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R, Zoulim F; Members of the ICE-HBV Working Groups., ICE-HBV Stakeholders Group Chairs., ICE-HBV Senior Advisors. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 2019;4:545-58. [PMID: 30981686 DOI: 10.1016/S2468-1253(19)30119-0] [Cited by in Crossref: 210] [Cited by in F6Publishing: 142] [Article Influence: 70.0] [Reference Citation Analysis]
62 Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, Delaugerre C, Girard PM, Zoulim F. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol. 2016;65:683-691. [PMID: 27210429 DOI: 10.1016/j.jhep.2016.05.014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 10.3] [Reference Citation Analysis]
63 Pronier C, Candotti D, Boizeau L, Bomo J, Laperche S, Thibault V. The contribution of more sensitive hepatitis B surface antigen assays to detecting and monitoring hepatitis B infection. J Clin Virol 2020;129:104507. [PMID: 32570044 DOI: 10.1016/j.jcv.2020.104507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
64 Podlaha O, Wu G, Downie B, Ramamurthy R, Gaggar A, Subramanian M, Ye Z, Jiang Z. Genomic modeling of hepatitis B virus integration frequency in the human genome. PLoS One 2019;14:e0220376. [PMID: 31356634 DOI: 10.1371/journal.pone.0220376] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
65 Ito K, Angata K, Kuno A, Okumura A, Sakamoto K, Inoue R, Morita N, Watashi K, Wakita T, Tanaka Y, Sugiyama M, Mizokami M, Yoneda M, Narimatsu H. Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus. Hepatol Res 2020;50:1128-40. [PMID: 32738016 DOI: 10.1111/hepr.13552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Yoshio S, Mano Y, Doi H, Shoji H, Shimagaki T, Sakamoto Y, Kawai H, Matsuda M, Mori T, Osawa Y, Korenaga M, Sugiyama M, Mizokami M, Mita E, Katayama K, Tanaka J, Kanto T. Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients. JCI Insight 2018;3:122268. [PMID: 30333304 DOI: 10.1172/jci.insight.122268] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
67 Revill PA, Tu T, Netter HJ, Yuen LKW, Locarnini SA, Littlejohn M. The evolution and clinical impact of hepatitis B virus genome diversity. Nat Rev Gastroenterol Hepatol 2020;17:618-34. [DOI: 10.1038/s41575-020-0296-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 30.0] [Reference Citation Analysis]
68 Li F, Cheng L, Murphy CM, Reszka-Blanco NJ, Wu Y, Chi L, Hu J, Su L. Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs. Sci Rep 2016;6:36483. [PMID: 27819342 DOI: 10.1038/srep36483] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
69 Duan J, Wu Y, Liu J, Zhang J, Fu Z, Feng T, Liu M, Han J, Li Z, Chen S. Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.J Hepatocell Carcinoma. 2019;6:151-166. [PMID: 31696097 DOI: 10.2147/JHC.S224849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
70 Arbuthnot P, Maepa MB, Ely A, Pepper MS. The state of gene therapy research in Africa, its significance and implications for the future. Gene Ther 2017;24:581-9. [PMID: 28692018 DOI: 10.1038/gt.2017.57] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
71 Rajbhandari R, Chung RT. Treatment of Hepatitis B: A Concise Review. Clin Transl Gastroenterol 2016;7:e190. [PMID: 27628420 DOI: 10.1038/ctg.2016.46] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
72 Yan H, Liu Y, Sui J, Li W. NTCP opens the door for hepatitis B virus infection. Antiviral Research 2015;121:24-30. [DOI: 10.1016/j.antiviral.2015.06.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
73 Lai F, Wee CYY, Chen Q. Establishment of Humanized Mice for the Study of HBV. Front Immunol 2021;12:638447. [PMID: 33679796 DOI: 10.3389/fimmu.2021.638447] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Maepa MB, Ely A, Grayson W, Arbuthnot P. Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs. Mol Ther Nucleic Acids 2017;7:190-9. [PMID: 28624194 DOI: 10.1016/j.omtn.2017.04.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
75 Allweiss L, Dandri M. The Role of cccDNA in HBV Maintenance. Viruses. 2017;9:156. [PMID: 28635668 DOI: 10.3390/v9060156] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 12.6] [Reference Citation Analysis]
76 Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease: An update. Hepatology 2015;62:1871-82. [PMID: 26340591 DOI: 10.1002/hep.28150] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
77 Jiang T, Su B, Song T, Zhu Z, Xia W, Dai L, Wang W, Zhang T, Wu H. Immunological Efficacy of Tenofovir Disproxil Fumarate-Containing Regimens in Patients With HIV-HBV Coinfection: A Systematic Review and Meta-Analysis. Front Pharmacol 2019;10:1023. [PMID: 31572195 DOI: 10.3389/fphar.2019.01023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Colpitts CC, Verrier ER, Baumert TF. Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections. ACS Infect Dis 2015;1:420-7. [PMID: 27617925 DOI: 10.1021/acsinfecdis.5b00039] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
79 Fourati S, Pawlotsky JM. Recent advances in understanding and diagnosing hepatitis B virus infection. F1000Res. 2016;5:pii: F1000. [PMID: 27635243 DOI: 10.12688/f1000research.8983.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
80 Kaneko M, Futamura Y, Tsukuda S, Kondoh Y, Sekine T, Hirano H, Fukano K, Ohashi H, Saso W, Morishita R, Matsunaga S, Kawai F, Ryo A, Park SY, Suzuki R, Aizaki H, Ohtani N, Sureau C, Wakita T, Osada H, Watashi K. Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide. Sci Rep 2018;8:2769. [PMID: 29426822 DOI: 10.1038/s41598-018-20987-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
81 Verrier ER, Colpitts CC, Schuster C, Zeisel MB, Baumert TF. Cell Culture Models for the Investigation of Hepatitis B and D Virus Infection. Viruses 2016;8:E261. [PMID: 27657111 DOI: 10.3390/v8090261] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
82 Schinazi RF, Ehteshami M, Bassit L, Asselah T. Towards HBV curative therapies. Liver Int 2018;38 Suppl 1:102-14. [PMID: 29427479 DOI: 10.1111/liv.13656] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 12.7] [Reference Citation Analysis]
83 Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. Journal of Hepatology 2016;64:S117-31. [DOI: 10.1016/j.jhep.2016.02.016] [Cited by in Crossref: 120] [Cited by in F6Publishing: 112] [Article Influence: 20.0] [Reference Citation Analysis]
84 Tang D, Zhao H, Wu Y, Peng B, Gao Z, Sun Y, Duan J, Qi Y, Li Y, Zhou Z, Guo G, Zhang Y, Li C, Sui J, Li W. Transcriptionally inactive hepatitis B virus episome DNA preferentially resides in the vicinity of chromosome 19 in 3D host genome upon infection. Cell Rep 2021;35:109288. [PMID: 34192543 DOI: 10.1016/j.celrep.2021.109288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Jacobs R, Singh P, Smith T, Arbuthnot P, Maepa MB. Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases. Gene Ther 2022. [PMID: 35606493 DOI: 10.1038/s41434-022-00342-5] [Reference Citation Analysis]
86 Lucifora J, Bonnin M, Aillot L, Fusil F, Maadadi S, Dimier L, Michelet M, Floriot O, Ollivier A, Rivoire M, Ait-Goughoulte M, Daffis S, Fletcher SP, Salvetti A, Cosset FL, Zoulim F, Durantel D. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. Sci Rep 2018;8:5390. [PMID: 29599452 DOI: 10.1038/s41598-018-23525-w] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
87 Pan J, Tong S, Kang L, Tang J. New anti-hepatitis B virus drugs under development and evaluation: . Current Opinion in Infectious Diseases 2016;29:632-8. [DOI: 10.1097/qco.0000000000000318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
88 Zhang X, Su H, Yu H, Ding J, Deng W, Qin B, Zhou C, Dou J, Guo M. A Polysaccharide From Eupolyphaga sinensis Walker With Anti-HBV Activities In Vitro and In Vivo. Front Pharmacol 2022;13:827128. [DOI: 10.3389/fphar.2022.827128] [Reference Citation Analysis]
89 Li Y, Liu H, Xu L. Expression of MMP-9 in different degrees of chronic hepatitis B and its correlation with inflammation. Exp Ther Med 2018;16:4136-40. [PMID: 30344689 DOI: 10.3892/etm.2018.6673] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Kremsdorf D, Strick-Marchand H. Modeling hepatitis virus infections and treatment strategies in humanized mice. Curr Opin Virol 2017;25:119-25. [PMID: 28858692 DOI: 10.1016/j.coviro.2017.07.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
91 Guo L, Liang Y. Expression of PBMC apoptosis-related factors in patients with chronic hepatitis B and their relationships with clinical prognosis. Exp Ther Med 2017;14:6007-11. [PMID: 29285150 DOI: 10.3892/etm.2017.5299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
92 Zheng J, Lin X, Wang X, Zheng L, Lan S, Jin S, Ou Z, Wu J. In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein. Viruses 2017;9:E112. [PMID: 28509875 DOI: 10.3390/v9050112] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
93 Lobaina Y, Michel ML. Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials. Vaccine 2017;35:2308-14. [PMID: 28351734 DOI: 10.1016/j.vaccine.2017.03.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
94 Murphy CM, Xu Y, Li F, Nio K, Reszka-Blanco N, Li X, Wu Y, Yu Y, Xiong Y, Su L. Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication. Cell Rep. 2016;16:2846-2854. [PMID: 27626656 DOI: 10.1016/j.celrep.2016.08.026] [Cited by in Crossref: 114] [Cited by in F6Publishing: 114] [Article Influence: 22.8] [Reference Citation Analysis]
95 Revill P, Locarnini S. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA). Current Opinion in Pharmacology 2016;30:144-50. [DOI: 10.1016/j.coph.2016.08.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
96 Besson C, Noel N, Lancar R, Prevot S, Algarte-Genin M, Rosenthal E, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Cheret A, Arvieux C, Katlama C, Salmon D, Boué F, Costello R, Hendel-Chavez H, Taoufik Y, Fontaine H, Coppo P, Mounier N, Delobel P, Costagliola D; Lymphovir and FHDH study groups. Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. AIDS 2020;34:599-608. [PMID: 31833850 DOI: 10.1097/QAD.0000000000002461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
97 Bhat SA, Kazim SN. HBV cccDNA─A Culprit and Stumbling Block for the Hepatitis B Virus Infection: Its Presence in Hepatocytes Perplexed the Possible Mission for a Functional Cure. ACS Omega. [DOI: 10.1021/acsomega.2c02216] [Reference Citation Analysis]
98 Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB. Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol. 2015;14:41-46. [PMID: 26262886 DOI: 10.1016/j.coviro.2015.07.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
99 Yang H, Chen P. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Research 2018;244:304-10. [DOI: 10.1016/j.virusres.2017.06.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
100 Ramírez-Soto MC, Ortega-Cáceres G, Cabezas C. Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: An analysis of death certificate data. Vaccine 2017;35:3808-12. [PMID: 28602606 DOI: 10.1016/j.vaccine.2017.05.086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
101 Passioura T, Watashi K, Fukano K, Shimura S, Saso W, Morishita R, Ogasawara Y, Tanaka Y, Mizokami M, Sureau C, Suga H, Wakita T. De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry. Cell Chem Biol 2018;25:906-915.e5. [PMID: 29779957 DOI: 10.1016/j.chembiol.2018.04.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
102 Ito K. Difference between genotypes B and C in the decline and disappearance of hepatitis B surface antigen: Toward an era of direct-acting antiviral agents for hepatitis B virus. Hepatol Res 2019;49:1253-5. [PMID: 31820538 DOI: 10.1111/hepr.13456] [Reference Citation Analysis]
103 Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016;36 Suppl 1:85-92. [PMID: 26725903 DOI: 10.1111/liv.13003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
104 Mukherji A, Dachraoui M, Baumert TF. Perturbation of the circadian clock and pathogenesis of NAFLD. Metabolism 2020;111S:154337. [PMID: 32795560 DOI: 10.1016/j.metabol.2020.154337] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
105 Boyd A, Canini L, Gozlan J, Lascoux-Combe C, Miailhes P, Fonquernie L, Girard PM, Lacombe K. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients. J Clin Virol 2017;95:55-60. [PMID: 28869890 DOI: 10.1016/j.jcv.2017.08.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
106 Thomas E, Liang TJ. Experimental models of hepatitis B and C - new insights and progress. Nat Rev Gastroenterol Hepatol. 2016;13:362-374. [PMID: 27075261 DOI: 10.1038/nrgastro.2016.37] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
107 Alfaiate D, Dény P, Durantel D. Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options. Antiviral Research 2015;122:112-29. [DOI: 10.1016/j.antiviral.2015.08.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
108 Levrero M, Subic M, Villeret F, Zoulim F. Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. Current Opinion in Virology 2018;30:80-9. [DOI: 10.1016/j.coviro.2018.04.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
109 Liu C, Cai D, Zhang L, Tang W, Yan R, Guo H, Chen X. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. Antiviral Res 2016;134:97-107. [PMID: 27591143 DOI: 10.1016/j.antiviral.2016.08.026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
110 Zhang X, Yue L, Zhang Z, Yuan Z. Establishment of a fluorescent in situ hybridization assay for imaging hepatitis B virus nucleic acids in cell culture models. Emerg Microbes Infect 2017;6:e98. [PMID: 29116221 DOI: 10.1038/emi.2017.84] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
111 van Campenhout MJ, Brouwer WP, van Oord GW, Xie Q, Zhang Q, Zhang N, Guo S, Tabak F, Streinu-Cercel A, Wang J, Pas SD, Sonneveld MJ, de Knegt RJ, Boonstra A, Hansen BE, Janssen HL. Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Microbiol Infect 2016;22:571.e5-9. [PMID: 26898481 DOI: 10.1016/j.cmi.2016.02.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
112 Huber AD, Wolf JJ, Liu D, Gres AT, Tang J, Boschert KN, Puray-Chavez MN, Pineda DL, Laughlin TG, Coonrod EM, Yang Q, Ji J, Kirby KA, Wang Z, Sarafianos SG. The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells. mSphere 2018;3:e00131-18. [PMID: 29669885 DOI: 10.1128/mSphereDirect.00131-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
113 Nakajima S, Watashi K, Fukano K, Tsukuda S, Wakae K, Aizaki H, Muramatsu M, Wakita T, Toyoda T. Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay. J Gastroenterol 2020;55:441-52. [PMID: 31768802 DOI: 10.1007/s00535-019-01643-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
114 Tu J, Li JJ, Shan ZJ, Zhai HL. Exploring the binding mechanism of Heteroaryldihydropyrimidines and Hepatitis B Virus capsid combined 3D-QSAR and molecular dynamics. Antiviral Research 2017;137:151-64. [DOI: 10.1016/j.antiviral.2016.11.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
115 Sureau C. A unique monoclonal antibody for therapeutic use against chronic hepatitis B: not all antibodies are created equal. Gut 2016;65:546-7. [PMID: 26611231 DOI: 10.1136/gutjnl-2015-310978] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
116 Goutam K, Ielasi FS, Pardon E, Steyaert J, Reyes N. Structural basis of sodium-dependent bile salt uptake into the liver. Nature 2022. [PMID: 35545671 DOI: 10.1038/s41586-022-04723-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
117 Yurdaydin C. Recent advances in managing hepatitis D. F1000Res 2017;6:1596. [PMID: 28928961 DOI: 10.12688/f1000research.11796.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
118 Qiao L, Sui J, Luo G. Robust Human and Murine Hepatocyte Culture Models of Hepatitis B Virus Infection and Replication. J Virol 2018;92:e01255-18. [PMID: 30232184 DOI: 10.1128/JVI.01255-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
119 Moradpour D, Grakoui A, Manns MP. Future landscape of hepatitis C research - Basic, translational and clinical perspectives. J Hepatol. 2016;65:S143-S155. [PMID: 27641984 DOI: 10.1016/j.jhep.2016.07.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
120 Liu SK, Seto W, Lai C, Yuen M. Hepatitis B: treatment choice and monitoring for response and resistance. Expert Review of Gastroenterology & Hepatology 2016;10:697-707. [DOI: 10.1586/17474124.2016.1145547] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
121 Bandiera S, Baumert TF, Zeisel MB. Circulating microRNAs for early detection of hepatitis B-related hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:198-200. [PMID: 27275459 DOI: 10.21037/hbsn.2016.03.08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821 [PMID: 34368300 DOI: 10.12998/wjcc.v9.i21.5812] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Fu L, Hu H, Liu Y, Jing Z, Li W. Woodchuck sodium taurocholate cotransporting polypeptide supports low-level hepatitis B and D virus entry. Virology 2017;505:1-11. [PMID: 28213271 DOI: 10.1016/j.virol.2017.02.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
124 Testoni B, Durantel D, Zoulim F. Novel targets for hepatitis B virus therapy. Liver Int. 2017;37 Suppl 1:33-39. [PMID: 28052622 DOI: 10.1111/liv.13307] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
125 Su T, Yang H, Tseng T, Liou J, Liu C, Chen C, Chen P, Chen D, Liu C, Kao J. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. The Journal of Infectious Diseases 2018;217:1193-201. [DOI: 10.1093/infdis/jix690] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
126 Ligat G, Verrier ER, Nassal M, Baumert TF. Hepatitis B virus-host interactions and novel targets for viral cure. Curr Opin Virol 2021;49:41-51. [PMID: 34029994 DOI: 10.1016/j.coviro.2021.04.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Xiong F, Bao X, Gu N, Guo J, Wang J, Ma Y, Yu L, Gao Y, Tan B, Lu J. The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk. Infect Genet Evol 2020;78:104101. [PMID: 31689542 DOI: 10.1016/j.meegid.2019.104101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
128 Zheng J, Ou Z, Lin X, Wang L, Liu Y, Jin S, Wu J. Analysis of epitope-based vaccine candidates against the E antigen of the hepatitis B virus based on the B genotype sequence: An in silico and in vitro approach. Cell Immunol 2018;329:56-65. [PMID: 29724463 DOI: 10.1016/j.cellimm.2018.04.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
129 Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, Hallett TB. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16:1399-1408. [PMID: 27638356 DOI: 10.1016/s1473-3099(16)30204-3] [Cited by in Crossref: 167] [Cited by in F6Publishing: 81] [Article Influence: 27.8] [Reference Citation Analysis]
130 Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL, Schluep T. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Res 2015;121:47-58. [PMID: 26092643 DOI: 10.1016/j.antiviral.2015.06.008] [Cited by in Crossref: 151] [Cited by in F6Publishing: 136] [Article Influence: 21.6] [Reference Citation Analysis]
131 Chabrolles H, Auclair H, Vegna S, Lahlali T, Pons C, Michelet M, Couté Y, Belmudes L, Chadeuf G, Kim Y, Di Bernardo A, Jalaguier P, Cosset FL, Fusil F, Rivoire M, Arnold LD, Lopatin U, Combet C, Zoulim F, Grierson D, Chabot B, Lucifora J, Durantel D, Salvetti A. Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production. PLoS Pathog 2020;16:e1008593. [PMID: 33180834 DOI: 10.1371/journal.ppat.1008593] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
132 Saso W, Tsukuda S, Ohashi H, Fukano K, Morishita R, Matsunaga S, Ohki M, Ryo A, Park SY, Suzuki R, Aizaki H, Muramatsu M, Sureau C, Wakita T, Matano T, Watashi K. A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction. Biochem Biophys Res Commun 2018;501:374-9. [PMID: 29730285 DOI: 10.1016/j.bbrc.2018.04.187] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
133 Cheng X, Guan W, Sun S, Li B, Li H, Kang F, Kang J, Yang D, Nassal M, Sun D. Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus. PLoS One 2015;10:e0145746. [PMID: 26699621 DOI: 10.1371/journal.pone.0145746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
134 Iwamoto M, Watashi K. Closing the door on hepatitis B and D virus entry: what are our therapeutic options? Future Virology 2016;11:715-8. [DOI: 10.2217/fvl-2016-0097] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Li C, Wang Y, Liu T, Niklasch M, Qiao K, Durand S, Chen L, Liang M, Baumert TF, Tong S, Nassal M, Wen Y, Wang Y. An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion. Antiviral Research 2019;162:118-29. [DOI: 10.1016/j.antiviral.2018.12.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
136 Dusséaux M, Masse-Ranson G, Darche S, Ahodantin J, Li Y, Fiquet O, Beaumont E, Moreau P, Rivière L, Neuveut C, Soussan P, Roingeard P, Kremsdorf D, Di Santo JP, Strick-Marchand H. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver. Gastroenterology 2017;153:1647-1661.e9. [PMID: 28851562 DOI: 10.1053/j.gastro.2017.08.034] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
137 Ozaras R, Khodor H, Yetim N, Unal UK, Demirhan YE, Gultekin G, Isal B. Monotherapy for hepatitis B infection: a review of treatment options. Expert Rev Anti Infect Ther 2015;13:1457-68. [PMID: 26414781 DOI: 10.1586/14787210.2015.1093934] [Reference Citation Analysis]
138 Yu Y, Ai J, Zhang W. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2017;11:925-37. [PMID: 28661190 DOI: 10.1080/17474124.2017.1343665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
139 Testoni B, Zoulim F. Liver capsule: Validated and potential novel targets to treat hepatitis B virus. Hepatology 2015;62:1619. [PMID: 26340325 DOI: 10.1002/hep.28144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
140 Limothai U, Chuaypen N, Poovorawan K, Chotiyaputta W, Tanwandee T, Poovorawan Y, Tangkijvanich P. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2019;26:1481-8. [PMID: 31446638 DOI: 10.1111/jvh.13195] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
141 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695-747. [PMID: 27281742 DOI: 10.1128/cmr.00102-15] [Cited by in Crossref: 592] [Cited by in F6Publishing: 276] [Article Influence: 98.7] [Reference Citation Analysis]
142 Kaneko M, Watashi K, Kamisuki S, Matsunaga H, Iwamoto M, Kawai F, Ohashi H, Tsukuda S, Shimura S, Suzuki R, Aizaki H, Sugiyama M, Park SY, Ito T, Ohtani N, Sugawara F, Tanaka Y, Mizokami M, Sureau C, Wakita T. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. J Virol 2015;89:11945-53. [PMID: 26378168 DOI: 10.1128/JVI.01855-15] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
143 Coggins SA, Mahboubi B, Schinazi RF, Kim B. SAMHD1 Functions and Human Diseases. Viruses 2020;12:E382. [PMID: 32244340 DOI: 10.3390/v12040382] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
144 Lin CL, Kao JH. Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther. 2016;44:213-222. [PMID: 27302653 DOI: 10.1111/apt.13694] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
145 Li BS, Sun DX. Role of covalently closed circular DNA in treatment of chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2016; 24(12): 1824-1831 [DOI: 10.11569/wcjd.v24.i12.1824] [Reference Citation Analysis]
146 Hardtstock F, Sbarigia U, Kocaata Z, Wilke T, Sylvester SV. Preferences of Patients with Chronic Hepatitis B - A Discrete Choice Experiment on the Acceptability of Functional Cure. Patient Prefer Adherence 2020;14:613-24. [PMID: 32256052 DOI: 10.2147/PPA.S238833] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Lee H, Shin B, Moon J, Fadriquela A, Nuwormegbe SA, Ho C, Shin J, Yoon J, Lee S, Kim S. Critical role of bile acid (BA) in the cellular entry and permissiveness of Hepatitis B virus in vitro. Mol Cell Toxicol 2020;16:221-31. [DOI: 10.1007/s13273-020-00081-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Nakajima S, Watashi K, Kato T, Muramatsu M, Wakita T, Tamura N, Hattori SI, Maeda K, Mitsuya H, Yasutake Y, Toyoda T. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations. J Virol 2021;95:e0240120. [PMID: 34076480 DOI: 10.1128/JVI.02401-20] [Reference Citation Analysis]
149 Soriano V, Barreiro P, Benitez L, Peña JM, de Mendoza C. New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2017;26:843-51. [DOI: 10.1080/13543784.2017.1333105] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
150 Chong CH, Lim SG. When can we stop nucleoside analogues in patients with chronic hepatitis B? Liver Int. 2017;37 Suppl 1:52-58. [PMID: 28052620 DOI: 10.1111/liv.13314] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
151 Wijaya RS, Read SA, Schibeci S, Han S, Azardaryany MK, van der Poorten D, Lin R, Yuen L, Lam V, Douglas MW, George J, Ahlenstiel G. Expansion of dysfunctional CD56-CD16+ NK cells in chronic hepatitis B patients. Liver Int 2021;41:969-81. [PMID: 33411395 DOI: 10.1111/liv.14784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
152 Wang YJ, Yang L, Zuo JP. Recent developments in antivirals against hepatitis B virus. Virus Res. 2016;213:205-213. [PMID: 26732483 DOI: 10.1016/j.virusres.2015.12.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
153 Heuschkel MJ, Baumert TF, Verrier ER. Cell Culture Models for the Study of Hepatitis D Virus Entry and Infection. Viruses 2021;13:1532. [PMID: 34452397 DOI: 10.3390/v13081532] [Reference Citation Analysis]
154 Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, Omagari K, Suzuki R, Aizaki H, Kojima S, Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T. A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins. Hepatology 2017;65:1104-16. [PMID: 27863453 DOI: 10.1002/hep.28952] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
155 Mukherji A, Bailey SM, Staels B, Baumert TF. The circadian clock and liver function in health and disease. Journal of Hepatology 2019;71:200-11. [DOI: 10.1016/j.jhep.2019.03.020] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 15.0] [Reference Citation Analysis]
156 Loglio A, Viganò M, Lampertico P. Novel Therapies That May Cure Chronic Hepatitis B Virus. Clin Liver Dis 2021;25:875-99. [PMID: 34593159 DOI: 10.1016/j.cld.2021.07.001] [Reference Citation Analysis]
157 van Campenhout MJH, Rijckborst V, Brouwer WP, van Oord GW, Ferenci P, Tabak F, Akdogan M, Pinarbasi B, Simon K, de Knegt RJ, Boonstra A, Janssen HLA, Hansen BE. Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:1156-63. [PMID: 31135084 DOI: 10.1111/jvh.13117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
158 Ni YH, Chang MH, Jan CF, Hsu HY, Chen HL, Wu JF, Chen DS. Continuing Decrease in Hepatitis B Virus Infection 30 Years After Initiation of Infant Vaccination Program in Taiwan. Clin Gastroenterol Hepatol. 2016;14:1324-1330. [PMID: 27155556 DOI: 10.1016/j.cgh.2016.04.030] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 9.3] [Reference Citation Analysis]
159 Kremsdorf D, Lekbaby B, Bablon P, Sotty J, Augustin J, Schnuriger A, Pol J, Soussan P. Alternative splicing of viral transcripts: the dark side of HBV. Gut 2021;70:2373-82. [PMID: 34535538 DOI: 10.1136/gutjnl-2021-324554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
160 Gonçalves A, Lemenuel-Diot A, Cosson V, Jin Y, Feng S, Bo Q, Guedj J. What drives the dynamics of HBV RNA during treatment? J Viral Hepat 2021;28:383-92. [PMID: 33074571 DOI: 10.1111/jvh.13425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
161 De S, Meredith L. A unique multiattribute method to predict success of emerging drug targets. Drug Discov Today 2016;21:385-94. [PMID: 26456731 DOI: 10.1016/j.drudis.2015.09.016] [Reference Citation Analysis]
162 Sun Y, Yu M, Qu M, Ma Y, Zheng D, Yue Y, Guo S, Tang L, Li G, Zheng W, Wang M, Guo D, Li C. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion. Am J Physiol Gastrointest Liver Physiol 2020;318:G162-73. [PMID: 31604033 DOI: 10.1152/ajpgi.00197.2019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
163 Chang Y, Choe WH, Sinn DH, Lee JH, Ahn SH, Lee H, Shim JJ, Jun DW, Park SY, Nam JY, Cho EJ, Yu SJ, Lee DH, Lee JM, Kim YJ, Kwon SY, Paik SW, Yoon JH. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. J Infect Dis 2017;216:1407-14. [PMID: 29029102 DOI: 10.1093/infdis/jix506] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
164 Verrier ER, Colpitts CC, Sureau C, Baumert TF. Hepatitis B virus receptors and molecular drug targets. Hepatol Int 2016;10:567-73. [DOI: 10.1007/s12072-016-9718-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
165 Boucle S, Bassit L, Ehteshami M, Schinazi RF. Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. Clin Liver Dis 2016;20:737-49. [PMID: 27742011 DOI: 10.1016/j.cld.2016.07.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
166 Tajiri K, Shimizu Y. New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol 2016; 8(21): 863-873 [PMID: 27478536 DOI: 10.4254/wjh.v8.i21.863] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
167 Huang H, Zhou W, Zhu H, Zhou P, Shi X. Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs. Toxicol Appl Pharmacol 2017;323:36-43. [PMID: 28322895 DOI: 10.1016/j.taap.2017.03.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
168 Boyd A, Duchesne L, Lacombe K. Research gaps in viral hepatitis. J Int AIDS Soc 2018;21 Suppl 2:e25054. [PMID: 29633564 DOI: 10.1002/jia2.25054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
169 Lebossé F, Inchauspé A, Locatelli M, Miaglia C, Diederichs A, Fresquet J, Chapus F, Hamed K, Testoni B, Zoulim F. Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients. Sci Rep 2020;10:21097. [PMID: 33273565 DOI: 10.1038/s41598-020-78001-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
170 Levrero M, Testoni B, Zoulim F. HBV cure: why, how, when? Curr Opin Virol. 2016;18:135-143. [PMID: 27447092 DOI: 10.1016/j.coviro.2016.06.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
171 Wang Y, Wang S, Tao X, Wang Y, Wu Y, Chen N, Hu C, Wang H, Yu S, Sheng R. The SAR-based development of small molecular HBV capsid assembly modulators. Med Chem Res. [DOI: 10.1007/s00044-022-02936-5] [Reference Citation Analysis]
172 Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81. [PMID: 26112647 DOI: 10.1016/j.antiviral.2015.06.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
173 Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol 2019; 11(1): 65-73 [PMID: 30705719 DOI: 10.4254/wjh.v11.i1.65] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
174 Yu Y, Li S, Liang W. Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets. Emerg Microbes Infect 2018;7:134. [PMID: 30050063 DOI: 10.1038/s41426-018-0137-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
175 Duvoux C, Belli LS, Fung J, Angelico M, Buti M, Coilly A, Cortesi P, Durand F, Féray C, Fondevila C, Lebray P, Martini S, Nevens F, Polak WG, Rizzetto M, Volpes R, Zoulim F, Samuel D, Berenguer M. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. Aliment Pharmacol Ther 2021;54:583-605. [PMID: 34287994 DOI: 10.1111/apt.16374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
176 Dubey AK, Kumar Gupta V, Kujawska M, Orive G, Kim N, Li C, Kumar Mishra Y, Kaushik A. Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases. J Nanostruct Chem. [DOI: 10.1007/s40097-022-00472-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
177 Kumar R, Pérez-Del-Pulgar S, Testoni B, Lebossé F, Zoulim F. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. Liver Int 2016;36 Suppl 1:72-7. [PMID: 26725901 DOI: 10.1111/liv.13001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
178 Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163-186. [PMID: 28042609 DOI: 10.20517/2394-5079.2016.05] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 10.7] [Reference Citation Analysis]
179 Cai D, Wang X, Yan R, Mao R, Liu Y, Ji C, Cuconati A, Guo H. Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. Antiviral Res. 2016;132:26-37. [PMID: 27185623 DOI: 10.1016/j.antiviral.2016.05.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
180 Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse AW, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut 2018;67:542-52. [PMID: 28428345 DOI: 10.1136/gutjnl-2016-312162] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 24.3] [Reference Citation Analysis]
181 Pan J, Tong S, Tang J. LncRNA expression profiles in HBV-transformed human hepatocellular carcinoma cells treated with a novel inhibitor of human La protein. J Viral Hepat 2018;25:391-400. [PMID: 29091324 DOI: 10.1111/jvh.12821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
182 Verrier ER, Yim SA, Heydmann L, El Saghire H, Bach C, Turon-Lagot V, Mailly L, Durand SC, Lucifora J, Durantel D, Pessaux P, Manel N, Hirsch I, Zeisel MB, Pochet N, Schuster C, Baumert TF. Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes. Hepatology 2018;68:1695-709. [PMID: 29679386 DOI: 10.1002/hep.30054] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
183 Revill PA, Locarnini SA. New perspectives on the hepatitis B virus life cycle in the human liver. J Clin Invest 2016;126:833-6. [PMID: 26901815 DOI: 10.1172/JCI86650] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
184 Michel ML. [Vaccination against hepatitis B: success and challenges]. Med Sci (Paris) 2016;32:739-45. [PMID: 27615182 DOI: 10.1051/medsci/20163208022] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
185 Shih C, Chou S, Yang C, Huang J, Choijilsuren G, Jhou R. Control and Eradication Strategies of Hepatitis B Virus. Trends in Microbiology 2016;24:739-49. [DOI: 10.1016/j.tim.2016.05.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
186 Liu J, Goicochea P, Block T, Brosgart CL, Donaldson EF, Lenz O, Gee Lim S, Marins EG, Mishra P, Peters MG, Miller V. Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation. Journal of Virus Eradication 2017;3:1-6. [DOI: 10.1016/s2055-6640(20)30302-2] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
187 Yang G, Liu Z, Yang J, Luo K, Xu Y, He H, Fu Q, Yu S, Wang Z. Quasispecies characteristics in mother-to-child transmission of hepatitis B virus by next-generation sequencing. J Infect 2017;75:48-58. [PMID: 28483405 DOI: 10.1016/j.jinf.2017.04.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
188 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 1805] [Cited by in F6Publishing: 1711] [Article Influence: 361.0] [Reference Citation Analysis]
189 Gallay P, Ure D, Bobardt M, Chatterji U, Ou J, Trepanier D, Foster R. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice. PLoS One. 2019;14:e0217433. [PMID: 31181107 DOI: 10.1371/journal.pone.0217433] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
190 Liu Y, Ruan H, Li Y, Sun G, Liu X, He W, Mao F, He M, Yan L, Zhong G, Yan H, Li W, Zhang Z. Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue. J Med Chem 2021;64:543-65. [PMID: 33369415 DOI: 10.1021/acs.jmedchem.0c01484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
191 Thongsri P, Pewkliang Y, Borwornpinyo S, Wongkajornsilp A, Hongeng S, Sa-Ngiamsuntorn K. Curcumin inhibited hepatitis B viral entry through NTCP binding. Sci Rep 2021;11:19125. [PMID: 34580340 DOI: 10.1038/s41598-021-98243-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]